Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hengli Zhao

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Current Neuropharmacology|May 17, 2018
P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic StrokeHengli Zhao, Yujie Chen, Hua Feng
Central-European Journal of Immunology|May 19, 2023
HMBOX1, a member of the homeobox family: current research progressYu Jiang, Hongli Mu, Hengli Zhao
Oncology Reports|July 18, 2018
Homeobox containing 1 inhibits liver cancer progression by promoting autophagy as well as inhibiting stemness and immune escapeHengli Zhao, Huifeng Jia, Qiuju Han, et al.
Chemical Science|December 22, 2022
Cutting-edge molecular modelling to unveil new microscopic insights into the guest-controlled flexibility of metal-organic frameworksHengli Zhao, Camille Pelgrin-Morvan, Guillaume Maurin, et al.
Die Pharmazie|December 11, 2020
Pharmacokinetics and tolerability of intravenous posaconazole in healthy Chinese volunteers: a randomized, open-label and single-dose studyWei Ji, Hengli Zhao, Shaomei Yang, et al.
Molecular Immunology|July 23, 2018
HMBOX1 in hepatocytes attenuates LPS/D-GalN-induced liver injury by inhibiting macrophage infiltration and activationHengli Zhao, Qiuju Han, Nan Lu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 26, 2022
Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic modelHengli Zhao, Yilin Wei, Kun He, et al.
Clinical Pharmacology in Drug Development|March 3, 2023
Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese ParticipantsXiaoran Zhang, Gexin Shi, Shaorong Li, et al.
Frontiers in Cell and Developmental Biology|February 7, 2022
Heme in Cardiovascular Diseases: A Ubiquitous Dangerous Molecule Worthy of VigilanceYuyang Guo, Hengli Zhao, Zhibin Lin, et al.
Discover Oncology|August 5, 2025
A ferroptosis-related risk model for non-coding RNA AC002331.1 in colon cancer: construction via competing endogenous RNA network analysisJiahui Liu, Chenning Zhang, Bao Ma, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Current Neuropharmacology|May 17, 2018
P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic StrokeHengli Zhao, Yujie Chen, Hua Feng
Central-European Journal of Immunology|May 19, 2023
HMBOX1, a member of the homeobox family: current research progressYu Jiang, Hongli Mu, Hengli Zhao
Oncology Reports|July 18, 2018
Homeobox containing 1 inhibits liver cancer progression by promoting autophagy as well as inhibiting stemness and immune escapeHengli Zhao, Huifeng Jia, Qiuju Han, et al.
Chemical Science|December 22, 2022
Cutting-edge molecular modelling to unveil new microscopic insights into the guest-controlled flexibility of metal-organic frameworksHengli Zhao, Camille Pelgrin-Morvan, Guillaume Maurin, et al.
Die Pharmazie|December 11, 2020
Pharmacokinetics and tolerability of intravenous posaconazole in healthy Chinese volunteers: a randomized, open-label and single-dose studyWei Ji, Hengli Zhao, Shaomei Yang, et al.
Molecular Immunology|July 23, 2018
HMBOX1 in hepatocytes attenuates LPS/D-GalN-induced liver injury by inhibiting macrophage infiltration and activationHengli Zhao, Qiuju Han, Nan Lu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 26, 2022
Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic modelHengli Zhao, Yilin Wei, Kun He, et al.
Clinical Pharmacology in Drug Development|March 3, 2023
Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese ParticipantsXiaoran Zhang, Gexin Shi, Shaorong Li, et al.
Frontiers in Cell and Developmental Biology|February 7, 2022
Heme in Cardiovascular Diseases: A Ubiquitous Dangerous Molecule Worthy of VigilanceYuyang Guo, Hengli Zhao, Zhibin Lin, et al.
Discover Oncology|August 5, 2025
A ferroptosis-related risk model for non-coding RNA AC002331.1 in colon cancer: construction via competing endogenous RNA network analysisJiahui Liu, Chenning Zhang, Bao Ma, et al.
Pageof 6